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Abstract: 
Background Depressive and anxiety disorders contribute to a high disease burden. This paper 
investigates whether concise formats of cognitive behavioural- and/or pharmacotherapy are 
equivalent with longer standard care in the treatment of depressive and/or anxiety disorders in 
secondary mental health care.  
Methods A pragmatic randomised controlled equivalence trial was conducted at five Dutch 
outpatient Mental Healthcare Centres (MHCs) of the Regional Mental Health Provider (RMHP) 
‘Rivierduinen’. Patients (aged 18-65 years) with a mild to moderate anxiety and/or depressive 
disorder, were randomly allocated to concise or standard care. Data were collected at baseline, 3, 
6 and 12 months by Routine Outcome Monitoring (ROM). Primary outcomes were the Brief 
Symptom Inventory (BSI) and the Web Screening Questionnaire (WSQ). We used Generalized 
Estimating Equations (GEE) to assess outcomes.  
Results Between March 2010 and December 2012, 182 patients, were enrolled (n = 89 standard 
care; n = 93 concise care). Both intention-to-treat and per-protocol analyses demonstrated 
equivalence of concise care and standard care at all time points. Severity of illness reduced, and 
both treatments improved patients general health status and subdomains of quality of life. 
Moreover, in concise care, the beneficial effects started earlier.  
Discussion Concise care has the potential to be a feasible and promising alternative to longer 
standard secondary mental health care in the treatment of outpatients with a mild to moderate 
depressive and/or anxiety disorder. For future research, we recommend adhering more strictly to 
the concise treatment protocols to further explore the beneficial effects of the concise treatment.  
 
The study is registered in the Netherlands Trial Register, number NTR2590. Clinicaltrials.gov 
identifier: NCT01643642. 
Keywords: Depressive and anxiety disorder; randomized controlled trial; equivalence trial; 
concise therapy; Routine Outcome Monitoring (ROM); routine secondary mental healthcare 
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1. Introduction 
Depression and anxiety disorders are highly prevalent, cause great suffering and 
disability, and have a large impact on society (Murphy et al., 2004;Wittchen et al., 2011; 
Buist-Bouwman et al., 2006; Murray & Lopez, 1997b; Murray & Lopez, 1997a). 
Fortunately, several effective psycho- and pharmacotherapeutic treatments are widely 
applied for these disorders (Cuijpers et al., 2013). However, they place a high demand on 
healthcare services (Gustavsson et al., 2011; Nutt, 2011; Smit et al., 2006). Offering these 
treatments in a more concise form without compromising effectiveness might mitigate 
this problem (Cape et al., 2010). In this paper, we report the clinical results of a 
pragmatic, randomized controlled equivalence trial. This entails comparing concise and 
standard care. We tested the hypothesis thatconcise care is ‘as effective as’ standard care 
delivered in a secondary outpatient setting. We focused on patients with mild to moderate 
illness severity because we assumed that since in most cases their illness is less 
complicated, they would react more favorable to a concise approach. In both conditions, 
patients are treated with psycho- and/or pharmacotherapy delivered in routine practice. 
However, in concise care the treatments are limited in time and in number of (weekly) 
sessions (maximum 7) and offered as first (brief) step in a stepped-care model (Haaga, 
2000; Davison, 2000). Standard care is not confined to a maximum number of sessions or 
limited time-period (van Fenema et al., 2012). Patient characteristics and treatment 
effectiveness are assessed with Routine Outcome Monitoring (ROM; de Beurs et al., 
2011), a standard monitoring procedure already in use in the participating outpatient 
clinics. We hypothesized that concise care is equally effective as (equivalent to) standard 
care 3, 6 and 12 months after baseline assessment.  
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2. Methods  
The methods were published previously (Meuldijk et al., 2012) and are summarized 
briefly here. The Medical Ethics Committee (MEC) of the Leiden University Medical 
Center (LUMC) approved the study. It involved a comprehensive protocol (titled 
“Psychiatric Academic Registration Leiden database”) which safeguarded the anonymity 
of patients and participants and ensured proper handling of the data. We followed 
consolidated standards for reporting randomised controlled equivalence trials (Hopewell 
et al., 2008; Moher et al., 2010; Piaggio et al., 2012). All participants provided written 
informed consent before study entry.  
 
2.1 Study design and participants 
A two-armed pragmatic randomised controlled equivalence trial was conducted at five 
outpatient Mental Health Clinics (MHCs). These clinics were part of Rivierduinen (RD), 
a secondary Regional Mental Health Provider (RHMP) in the province of South-Holland, 
the Netherlands. Eligible participants were patients referred to the MHCs by their general 
practitioners (GP), aged 18-65 years, and meeting the DSM IV-TR criteria for a primary 
current diagnosis of anxiety disorder and/or depression, established using the Mini-
International Neuropsychiatric Interview-Plus, version 5.0.0 (MINI-Plus; Sheehan et al., 
1998; van Vliet & de Beurs, 2007). For a list of included diagnoses see Appendix A, 
Table I. Excluded were patients with suicidal or homicidal risk, severe social dysfunction, 
delusions, hallucinations and/or suffering from bipolar or psychotic disorders. Other co-
morbidity with psychiatric disorders was allowed. The inclusion (and exclusion) criteria 
for enrolling subjects in this study enduced a study sample of patients suffering from mild 
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to moderate anxiety and/or depressive disorders (APA, 1994). Insufficient mastery of 
Dutch was a reason for exclusion. Experienced psychiatrists at the MHCs determined 
study eligibility (Meuldijk et al., 2012). Eligible participants were randomly assigned to 
concise or standard care and assessed by ROM at baseline (T1), 3 (T2), 6 (T3) and 12 (T4) 
months thereafter.  
 
2.2. Randomisation and masking 
A block randomisation scheme, stratified by MHC (n = 5) and gender was used. 
Randomisation was carried out by one of the researchers (D.M.). Patients and therapists 
were informed about the outcome; the psychiatric test nurses responsible for the ROM 
assessments were not (Meuldijk et al., 2012).   
 
2.3 Treatment 
The treatment protocols in both conditions followed the Dutch and international 
guidelines for the evidence-based treatment of depressive and anxiety disorders. In both 
concise and standard care, a choice could be made between pharmacotherapy with a 
selective serotonin reuptake inhibitor (SSRI; (Guy, 1976), Cognitive Behavioural 
Therapy (CBT; Clark & Salkovskis, 1987; Beck, 1995; Clark & Salkovskis, 1987) and, in 
case of a posttraumatic stress disorder, Eye Movement Desensitization and Reprocessing- 
therapy (EMDR; Shapiro, 1995). A combination of pharmaco- and psychotherapy was 
also possible. In standard care the number of sessions, start and duration of treatment is 
variable and treatment could continue during the entire study period of 1 year. On 
average, psychotherapy is provided in 3-6 months on a weekly basis, but in practice once 
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every 2 to 3 weeks, pharmacotherapy for 1 year or longer (van Fenema et al., 2012). In 
contrast, concise care started within one week after the baseline measurement and had to 
be given within 7 weeks thereafter. Concise care was initially described as 4 to maximum 
7 individual 45-minute psychotherapy sessions, depending on the treatment protocol (see 
also Meuldijk et al. 2012). The pharmacotherapy protocol for depressive and/anxiety 
disorders in concise care was confined to a maximum of 4 sessions within 7 weeks.  
Moreover, therapists’ treatment choice in both standard and concise care followed the 
principles of shared decision-making (Hamann et al. 2003; Joosten et al. 2008). Contrary 
to standard care, treatment goals and procedures in concise care are clearly established 
and mutually agreed on, prior to initiating treatment. In addition, treatment success of 
concise care was evaluated at the end of treatment. When either the patient or therapist is 
convinced that the clinical effects are insufficient or patients are insufficiently helped by 
the initial treatments in concise care, ‘stepping up’ or continuation of (additional) 
standard treatment, in line with stepped-care principles, was possible (Haaga, 2000; 
Davison, 2000). Pharmacotherapy in concise care was also evaluated after 7 weeks, and 
continued when necessary according to the (inter) national clinical guidelines. After 
implementation changes to the treatment protocols were made at the recommendation of 
the MHCs; these included extending the treatment duration of concise care to a maximum 
of 7 sessions in 7-9 weeks. This was to allow treatment continuation of concise care in 
case of canceled or missed sessions by therapists or patients.  
 
Therapists providing concise care received a 2 hours instruction in the core elements of 
the intensified psychotherapy and/or pharmacotherapy, as described in the protocols. 
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Therapists in the standard condition did not get additional training (Meuldijk et al., 2012). 
The same therapists were responsible for delivering standard and concise care. All 
sessions in concise care were audiotaped for post-hoc assessment of treatment fidelity. 
Sufficient treatment protocol-adherence (>75%) was demonstrated in a random sample of 
20 patients with a satisfactory overall agreement between two independent raters 
(Cohen’s Kappa: 0.74).  
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3. Measures 
3.1. Routine Outcome Monitoring (ROM) 
ROM is a computer-based system to routinely assess symptom severity and functioning 
with an extensive battery of psychometric instruments. ROM is administered as part of 
the intake procedure (at baseline) and repeatedly during and after treatment (de Beurs et 
al.(de Beurs et al., 2011). In the present trial, measures of participants characteristics 
were collected at baseline, while symptom measures were administered at each time point 
(see also Meuldijk et al., 2012). An overview of ROM instruments at the different time-
points, is given in Appendix A, Table 2.  
 
3.2. Outcomes 
The Brief Symptom Inventory (BSI; (Derogatis, 1975) and the Web Screening 
Questionnaire (WSQ(Donker et al., 2009) constituted the primary outcome measures in 
this study. The secondary measures used were the Clinical Global Impression (CGI(Guy, 
1976) and the Short- Form-36 Health Survey (SF-36; (Ware et al., 1993;Aaronson et al., 
1998). Additionally, patients satisfaction with their care was explored by The Dutch 
Mental Healthcare Thermometer of Appreciation by Clients ((Kok & van, 2003).  
 
3.2.1. Primary outcomes 
Brief Symptom Inventory (BSI; (Derogatis, 1975). This patient-rated, 53 item 
questionnaire which is based on the Symptom Checklist (SCL-90(Derogatis & 
Melisaratos, 1983) assesses psychopathological symptom severity on a 5-point Likert 
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scale (from 0 ‘not at all’ to 4 ‘extremely’). The BSI total score, most indicative of general 
psychopathology, was computed as the mean score of all individual items (range 0-4).   
Web Screening Questionnaire (WSQ; (Donker et al., 2009). This is a self-rated, 15 item 
questionnaire which is based on the screening questionnaire (SQ) of Marks and 
colleagues. It is used as a quick tool to screen patients for most common mental disorders 
(Gega et al., 2005). The WSQ has 8 ‘yes’ or ‘no’ answers, the other 7 are Likert-type 
scales. Response was defined as a score above the pre-specified threshold for being 
diagnosed with any particular WSQ diagnosis (Donker et al., 2009). 
 
3.2.2. Secondary outcomes 
Clinical Global Impression (CGI; (Guy, 1976) This is a clinician rated scale that assesses 
illness severity. The main item ‘severity of illness’ measured on a 7-point Likert scale 
(from 1 ‘normal, not at all ill’ to 7 ‘among the most extremely ill patients’) is used in the 
present analyses. 
The Short Form-36 Health Survey (SF-36; (Ware et al., 1993;Aaronson et al., 1998). This 
self-report questionnaire assesses current general health status and quality of life in eight 
domains (36 items). Measurement scales vary per subscale, ranging from yes/no to 
answers on 3-, 5-, or 6-point Likert scale. All raw scores are linearly converted to a 0-100 
subscale, with higher scores representing better functioning/quality of life.  
In this paper, we report the changes in scores on the three SF-36 subscales which are 
primarily indicative of physical and mental health (Ware et al. 1994; 2000): physical 
functioning, social functioning and general health.  
9 
 
The Dutch Mental Healthcare Thermometer of Appreciation by Clients (Kok & van, 
2003). The thermometer contains 18 items; 17 items with ‘yes’ or ‘no’ answers, and one 
question on ‘overall satisfaction with care’, (scores from 1 to 5, higher scores indicating 
more satisfaction). Two additional items with an open answer format were not included 
here.  
 
3.3. Equivalence margins 
The study was designed to demonstrate therapeutical equivalence between concise and 
standard care and follows study procedures already published in Meuldijk et al. 2012. 
The sample size calculation (see (Meuldijk et al., 2012) indicated that 500 patients 
(alpha=0·05, 1 – β=0·80, two-sided) were required to demonstrate equivalence (Jones et 
al., 1996). Concise care will be deemed equivalent to standard care, if the 95% 
confidence interval (CI) for the observed difference in the proportions of treatment 
success (defined as a 50% reduction in BSI score compared to baseline BSI score) do not 
cross these predefined clinical margins of equivalence (∆) of  -15% and  + 15% including 
an acceptable difference of 5% (Meuldijk et al., 2012; Wiens, 2002; Jones et al., 1996). 
The equivalence margins are specified a priori on the basis of a clinical notion of 
detection, a minimally clinically important difference in effect (see Meuldijk et al.2012). 
If the treatment effects of concise and standard care differ by more than this equivalence 
margin in either direction, then equivalence does not hold.  
Although not powered for, we similarly evaluated equivalence for WSQ remission 
(defined as a score below the pre-specified threshold for being diagnosed with any WSQ 
diagnosis) at 6 and 12 months’ measurements. We performed both intention-to-treat 
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analyses and sensitivity analyses on the per protocol population (patients who completed 
both the baseline and the subsequent measurement) to test therapeutic equivalence.  
 
3.4. Statistical analysis 
We used descriptive statistics for the comparison of the baseline demographic and 
clinical variables between the groups that completed the treatment (completer group) and 
the group as randomised; t-tests were used for continuous measures and chi-square tests 
for categorical data. The margins of the 95% CIs on the basis of the observed difference 
in the proportions of treatment success of the primary outcomes were compared with the 
pre-determined equivalence margins. Equivalence was tested in both the intention-to-
treat and per protocol population. 
Additionally, Generalized Estimating Equation (GEE) models (Zeger & Liang, 
1986;Twisk, 2004) were used to estimate the mean differences between treatment groups 
and the confidence intervals (CIs) at each assessment point for both primary and 
secondary continuous outcomes; odds ratios with 95% CIs were given for dichotomous 
outcomes and differences in means for continuous outcomes. Since our GEE models 
yields odds ratios as the effect measure instead of risk ratios, effect-sizes are not 
presented. 
For all GEE analyses, the predictor variables were: time (baseline (T1) as reference, 
versus 3 (T2), 6 (T3) and 12 month (T4) measurement); treatment group (concise care 
versus standard care), and interaction between time and treatment group. An unstructured 
correlation matrix was specified in the GEE model to account for the within-patient 
correlation (repeated, longitudinal observations).  
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To investigate if results were overly optimistic due to drop-out of those with less 
favorable outcome, GEE analyses were repeated with imputation of missing data, by 
carrying the last observation forward method. Patient satisfaction was explored by 
between-group comparisons of two sample t-tests for continuous variables. GEE analyses 
for both primary and secondary outcomes were on an intention-to-treat basis using IBM 
SPSS version 20 (Windows). Significance for all statistical tests was set at a p-value < 
0.05 (two-sided).  
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4. Results 
Randomisation and treatment allocation took place between March, 2010 and December, 
2011. Follow-up assessments were completed for all patients in January, 2013. The 
passage of the participants through the study is depicted in the CONSORT Flow diagram 
in Figure 1.  
 
 Insert Figure 1  here 
 
A total of 182 eligible participants provided informed consent and completed the baseline 
assessment; 93 were randomised to concise care and 89 to receive standard care. 57% of 
the participants completed the 3-month assessment (n = 104). At assessments T3 and T4, 
(see Figure 1), respectively n = 65 and n = 42 had outcome data.  
 
4.1. Descriptive statistics  
The socio-demographic and clinical characteristics of the randomised sample and patients 
who completed both the baseline and the 3-month measurement (completer sample) are 
summarized in Table 1. Demographic data were available for 178 patients (98%). The 
MINI-Plus was administered in 181 patients (99%). 
 
 Insert Table 1 here 
 
Randomisation reasonably balanced the treatment groups with respect to the baseline 
characteristics. No statistical differences in baseline clinical or demographic 
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characteristics were found between patients who entered the trial and those who dropped 
out after baseline assessment. These p-values ranged  from  p = 0.061 to p = 0.892. In 
addition, we found no evidence of selective attrition on baseline measures (i.e. primary 
outcomes) between completers and dropouts (data not shown). According to the MINI-
Plus interview, 39% (n = 70) of the total sample suffered from depressive (with or 
without anxiety) disorder and 31% (n = 82) from anxiety (with or without depressive) 
disorder(s). Comorbidity between anxiety and depression was found in 17% (31 patients). 
34 patients (19%) did not pass the threshold for having any current Axis- I DSM-IV-TR 
diagnosis according to the MINI-Plus interview. These patients did seek professional help 
for their (subthreshold) depressive and/or anxiety complaints or symptoms.  
 
4.2. Treatment received  
During the entire study-period, 47 (25%) of all 182 patients, did not enter treatment 
(concise care, n = 24 of 93; standard care, n = 23 of 89). The majority of patients (61%) 
started treatment within 3 months after the baseline assessment (concise care, n = 63 
(91%); standard care n = 48 (73%)). The majority of these patients were offered 
psychotherapy (concise care, n = 49 (78%); standard care n = 37 (77%)). Only a small 
number of patients were offered pharmacotherapy (concise care, n = 4 (6%); standard 
care, n = 6 (13%)) or a combination of both therapies (concise care n = 10 (16%); 
standard care n = 5 (10%)). In addition, with concise care, the number of therapy sessions 
(i.e. face to face contacts) was on average as prescribed in the treatment protocols: six 
sessions for psychotherapy and one for pharmacotherapy. Compared with standard care, 
the number of therapy sessions did not differ significantly (all P values > 0.05). Patients 
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in the standard care group had on average three psychotherapy and one pharmacotherapy 
sessions (face to face contacts), within the first 3 months after baseline assessment. After 
the initial 3 months, 18 (27%) of the patients in standard care and 7 (10%) of the patients 
allocated to concise care actually started treatment. The number of patients who remitted 
or continued treatment after 12 months is unknown. No adverse events were reported.  
 
4.3. Equivalence: BSI and WSQ 
Table 2 presents the mean differences in the proportions of treatment success of BSI and 
WSQ and 95% CIs for both treatment groups over time for the intention-to-treat and the 
per protocol analysis.  
 
   Insert Table 2 here 
 
The results of Table 2 are visualized in Figure 2. In the intention-to-treat analysis, 
equivalence of concise and standard care could be demonstrated at T3 and T4 for the 
primary outcome measures BSI and WSQ. At assessments T3 and T4  the two-sided 95% 
CI’s for the difference in the proportions of treatment success for BSI and WSQ scores 
are within the predetermined equivalence margins (∆) of -15% and +15%. Furthermore, 
at T2, the right margin of the 95% CI of the difference in BSI improvement crosses the ∆ 
margin (> +15%) in favor of concise care .   
 
In the per protocol analysis, equivalence of concise and standard care for BSI 
improvement and WSQ remission has been neither proved or disproved. At T2, T3 and T4, 
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the right margins of the 95% CI’s for the difference in the proportions of treatment 
success of the BSI outcome measure cross the ∆ margins (> +15%)  in the per protocol 
analysis in favor of concise care. In addition, at T3 and T4 both left and right margins of 
the 95% CI of WSQ remission cross the ∆ margins, not establishing equivalence 
 
 Insert Figure 2 here 
 
4.4. GEE analyses: Primary and Secondary outcomes 
4.4.1. Primary outcomes  
Figure 3 presents the mean BSI scores and percentage of patients with a psychiatric 
disorder according to the WSQ at the different assessment points; severity of 
psychopathology in both treatment groups decreased over time. Furthermore, GEE 
analyses showed  that the difference in BSI scores between groups was the largest 3 
months after baseline and in favor of concise care (see Appendix B, Table 1). 
 
 Insert Figure 3 here 
 
4.4.2. Secondary outcomes  
Mean secondary outcomes scores during treatment for both groups are presented in 
Figure 4. The Clinical Global Impression scores reduced over time. Likewise, general 
health and quality of life improved in both treatment groups. GEE analyses showed 
statistically significant differences in effectiveness 3 and 12 months after baseline 
assessment in favor of concise care (see Appendix B, Table 2). 
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 Insert Figure 4 here 
 
All analyses using imputation with last observation carried forward for the missing data 
yielded similar results. Since randomization had been successful, we did not explore all 
possible confounders. Adjusting for age and gender did not influence the differences 
between the concise and standard care group for any of the primary or secondary 
outcomes (data not shown).  
 
Satisfaction with treatment. Patient satisfaction with treatment was measured 3 months 
after baseline in 81 patients (missing data in 23 patients). On average, patients in the 
concise treatment group (n = 41) were more satisfied with overall treatment than patients 
in standard care (mean item difference 1.04; p = 0.024). Satisfaction with the therapist did 
not differ significantly between groups (p = 0.205).  
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5. Discussion 
In this study we demonstrated that a novel 7-sessions concise version of cognitive 
behavioural therapy and/or pharmacotherapy led to comparable clinical outcomes as the 
longer standard care in the treatment of depressive and/or anxiety disorders in secondary 
care outpatients. This was true at the end of concise care at 3 months, but also later at 6 
and 12 months and for all effect parameters. In fact, in concise care, the clinical effects 
are obtained earlier, in the first phase of treatment. Moreover, patients were more 
satisfied with treatment in concise care.  
These results are in line with other studies on the effectiveness of brief treatments for 
depressive and anxiety disorders (Cape et al., 2010; Nieuwsma et al., 2011; van Straten et 
al., 2006; Ehlers et al., 2014). Although we cannot state with certainty what underlies the 
beneficial effect of concise care compared to standard care, we can hypothesize it. 
Therapists and patients had a central role in treatment. They were asked to strictly 
following the treatment protocols and actively participate in the study. Besides, prior to 
starting therapy, treatment goals were formulated and mutually agreed on by both the 
patient and therapist. These facts, could have also impacted the treatment outcome of 
concise care. Clinicians and patients could be highly motivated, contributing to this 
positive treatment effect. 
Our study is one of the first to demonstrate these effects in secondary mental health care. 
Treatment was provided in a regular ‘real life’ psychiatric outpatient sample by qualified 
therapists already working in the participating MHCs, reflecting day-to-day clinical 
practice. This increases external validity, thereby enhancing the generalizability of the 
results to clinical practice. Moreover, our study has good internal validity as is 
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demonstrated by the successful randomization of the treatment groups, the sufficient 
treatment fidelity and delivery of treatment according to protocols. However, several 
potential methodological concerns have to be noted. Firstly, the desired sample size of 
500 patients was not achieved. An investigation of the inclusion during a 2 month period 
showed that the majority of patients seeking treatment at the MHCs did not meet the trial 
inclusion criteria of our study because of the higher severity and burden of disease. 
Secondly, a substantial number of patients did not complete treatment or were lost to 
assessment, a common problem in long-term studies in naturalistic out-patient settings 
(van Noorden et al., 2012; Rush et al., 2006; van Straten et al., 2006).  
However, although we did not achieve the intended sample size of 500 patients we did 
find concise care to be at least as effective as concise care. Contrary to our initial 
expectations and assumptions of a real difference in percentages success between the 
treatments of 5% in either direction, the observed difference between the two treatments 
was larger than expected; e.g. 13% in favor of concise care in the intention-to-treat 
population at three months for the primary outcome measure BSI. The observed 
differences in success percentages at the three time points all being in favor of concise 
turned out to be sufficient to compensate for the loss to follow-up of patients. Another 
limitation is that because of the pragmatic study design, patient’s suitability to participate 
in the trial during the course of the study was assessed by the therapists involved. 
Unfortunately, the reasons for excluding patients from care during the trial were not 
adequately reported. Due to this lack of knowledge, we cannot make any statements 
about post-randomisation drop-out and reasons for loss to follow-up after study entry. 
However, concise care, as such, did not increase dropout rates significantly when 
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compared to standard care. In both groups a comparable number of patients had to be 
excluded, dropped out or did not visit the clinic as scheduled. We found no evidence for 
selective attrition on baseline characteristics, and our conservative handling of missing 
data, with last observations carried forward, did not alter the patterns of outcomes. An 
additional limitation, associated with the pragmatic study design, was that in practice, 
treatment and therapist adherence to the protocols in concise care was not optimal; not all 
patients were offered concise care as prescribed in the treatment protocols. Moreover, the 
design of the study as a RCT in a pragmatic setting resulted in considerable differences in 
follow-up periods between patients and groups. Although the majority of patients were 
offered concise care within the first 3 months after study entry, the duration of concise 
care was prolonged and continued during the entire study period (i.e. therapy sessions in 
concise care were delivered in 7-9 weeks). However, it appears that concise care did a 
better job of engaging patients in treatment in a more timely manner. This is reflected in 
the higher patient satisfaction rating for concise care reported at 3 months. In conclusion, 
we found that concise care is equally effective as standard care in the secondary 
outpatient treatment of depressive- and/or anxiety disorders. The early start of concise 
care, the strict scheduling of weekly patient-therapist contacts and the ongoing 
monitoring of treatment outcome are important for the beneficial effects of the concise 
treatment. Since concise care is likely to provide significant health gain, and most 
beneficial effects are obtained within the first phase of treatment, concise care is 
recommended as first step in a stepped-care delivery of care. Moreover, in contrast to 
other studies, concise care examined here follows a stratified stepped-care approach 
taking into account patients’ needs and preferences which may be clinically more 
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adequate than the more stringent model of stepped-care which begins with the least 
intensive treatment for each patient regardless of the patients needs and circumstances.  
Because the study was carried out in a naturalistic setting, the generalizability of the 
results is good. The study population reflects the subgroup of lighter cases referred to 
secondary care, therefore the findings of our study are generalizable to a broader patient 
population. However, the problems with the inclusion of patients and the high drop-out 
rate may decrease the generalizability, but these problems are also very difficult to avoid 
in a naturalistic setting. We hope that future studies with a larger sample size, longer 
follow-up and more strict adherence to the study protocol, will confirm our promising 
findings.  
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Table 1 
Socio-demographic and clinical characteristics of the two treatment groups at baseline measurement. 
          
 Total Randomised Sample  Completer sample   
  Standard care Concise care Standard care Concise care  
Baseline characteristics n  = 182 n = 89 n = 93 n = 52 n = 52 p - valuea 
Socio-demographicsb       
Age (years): mean (SD)   36.5       (12.3) 37.0     (11.98) 36.0       (12.0) 37.8        (11.8) 38.3      (13.1) 0.83 
Gender        
Female 111      (61%) 53 (60%) 58 (62%) 29 (56%) 31 (60%) 0.84 
Ethnical background c       
Dutch 167 (94%) 84 (94%) 83 (94%) 50 (96%) 47 (94%) 0.96 
Other    10   (6%)   5    (6%)   5   (6%)   2   (4%)   3   (6%)  
Education leveld       
Lower education   68 (38%) 34 (38%) 34 (39%) 19 (37%) 16 (32%) 0.78 
Higher education 109 (62%) 55 (62%) 54 (61%) 33 (64%) 34 (68%)  
Employment status            
Employed   90 (51%) 49 (55%) 41 (47%) 25 (49%) 24 (48%) 0.99 
Unemployed/retired   87 (49%) 40 (45%) 47 (53%) 27 (52%) 26 (52%)  
Marital status            
Married/Cohabitating    93 (53%) 42 (47%) 51 (58%) 24 (46%) 37 (74%) 0.01 
Clinical characteristics/MINI-Plus Diagnosise            
Any Depressive disorder   70 (39%) 36 (20%) 34 (19%) 22 (21%) 18 (18%) 0.49 
Any Anxiety disorder    82 (45%) 36 (20%) 46 (25%) 23 (22%) 29 (28%) 0.38 
Panic disorder (without agoraphobia)    25 (14%) 11   (6%) 14   (8%)   9 (17%)   8 (15%) 0.56 
Agoraphobia (without panic disorder)   38 (21%) 17   (9%) 21 (12%) 12 (23%) 13 (25%) 0.81 
Panic disorder with agoraphobia    19 (10%)   8   (4%) 11   (6%)   6 (12%)   6 (12%) 0.90 
Social phobia      9   (5%)   3   (2%)   6   (3%)   1    (2%)   3   (6%) 0.78 
Specific phobia     3   (2%)   1   (1%)   2   (1%)   1    (2%)   2   (4%) 0.99 
Generalized anxiety disorder   23 (13%) 11   (6%) 12   (7%)   5  (10%)   7 (14%) 0.99 
Posttraumatic stress disorder   15    (8%)   7   (4%)   8   (4%)   2    (4%)   6 (12%) 0.42 
Obsessive compulsive disorder     3   (2%)   2   (1%)   1   (1%)   1    (3%)   0   (0%) 0.91 
Depressive and anxiety disorder   31 (17%) 14   (8%) 17   (9%)   7  (14%) 10 (19%) 0.99 
       No current DSM IV- TR diagnosis   34 (19%) 19 (22%) 15 (16%)   5     (5%)     7   (7%)  0.79 
            
 
Results are presented as numbers (percentages) for categorical variables and means ± (standard deviation [SD]) for continues variables. DSM- IV-TR: Diagnostic and Statistical Manual of Mental 
Disorders; 4th edition. MINI-Plus: mini-international neuropsychiatric interview-plus.  
aP-values denotes the differences between standard vs. concise care in the completers sample. bDemographic data; ethnic background, educational status and employment status are missing for 5 
participants. cDutch ethnic background was assumed when the patient and both parents were born in the Netherlands.dLower education= having completed elementary school, lower general primary 
education or no education at all; higher education= more than lower education (includes university).eClinical characteristics/diagnosis was missing for 1 participant.  
 
Note. Patients may have more than one MINI-Plus diagnosis, comorbidity was allowed.
Table 2 
Observed differences in the percentages of treatment success over 12 months in the Intention-to-Treat and Per-protocol analysis. 
 
Estimated  differences in proportions and 95% CI are presented. 
BSI: Brief Symptom Inventory; WSQ: Web Screening Questionnaire. T2: 3 month assessment; T3: 6 month assessment; T4: 12 month assessment.
  
  
Intention-to-treat  
 
  
  Standard care  Concise care  Difference in proportions 95% CI 
      
BSI improvement T2 0.10 0.23 0.13  0.02 to 0.23 
 T3 0.15 0.18 0.04 -0.07 to 0.15 
 T4 0.11 0.16 0.05 -0.05 to 0.15 
      
WSQ remission  T3 0.05 0.03 0.01 -0.05 to 0.08 
 T4 0.06 0.05 0.00 -0.08 to 0.08 
      
  
  
Per-protocol  
 
  
  Standard care Concise care  Mean difference 95% CI 
      
BSI improvement T2 0.18 0.42 0.24  0.06 to 0.40 
 T3 0.38 0.63 0.25 -0.00 to 0.46 
 T4 0.46 0.75 0.30    -0.00 to 0.53 
      
WSQ remission  T3 0.15 0.16 0.01   -0.20 to 0.25  
 T4 0.23 0.29 0.07 -0.20 to 0.34  
      
 
 
 
 
Fig. 1. CONSORT Flow diagram.  
 
T1: baseline assessment; T2: 3 month assessment; T3: 6 month assessment; T4: 12 month assessment. 
 
*Reasons for post-randomisation drop-out after study entry are not known.
WSQ
BSI
 
 
Intention-to-Treat population 
  
      
Per protocol population        
 
 
Fig. 2. Equivalence figure BSI and WSQ; Intention-to-Treat analyses vs. Per protocol analyses. 
Horizontal bars indicate two-sided 95% confidence interval (CI) of  the percentage difference in 
proportions success between concise care and standard care. The zone between the vertical dashed lines at 
x = - ∆/+∆ indicates the equivalence margin. BSI: Brief Symptom Inventory; WSQ: Web Screening 
Questionnaire. T2: 3 month assessment; T3: 6 month assessment; T4: 12 month assessment. 
Standard care
Concise care  
 
 
 
 
 
 
Fig. 3. Observed mean (SE) changes in the primary outcome measure BSI and number of patients being 
diagnosed with any WSQ disorder in both treatment groups over time. 
 
BSI: Brief Symptom Inventory; WSQ: Web Screening Questionnaire. 
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Standard care
Concise care  
 
 
 
 
 
 
 
Fig. 4. Observed mean (SE) changes in the secondary outcome measures CGI and SF-36 scores over time 
in both treatment groups. 
 
CGI: Clinical Global Impression; SF-36: Short-Form Health Survey (SF-36 higher scores representing 
better functioning/quality of life).
Appendix A  
 
Table A. 1 
 
DSM IV-TR diagnoses included within study. 
 
Note: Co-morbidity associated with other psychiatric diagnosis (with the exception of psychotic or bipolar disorder) is allowed.  
 
NOS: Not Otherwise Specified.
Included DSM  IV-TR diagnoses  
minor or major depressive disorder (single episode or recurrent) 
depressive disorder NOS 
Dysthymia 
panic disorder (with or without agoraphobia) 
panic disorder NOS 
social phobia 
simple phobia 
generalized anxiety disorder 
obsessive compulsive disorder 
posttraumatic stress disorder (type I or single trauma), 
adjustment disorder (with anxiety and/or depressive mood). 
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Appendix A  
 
Table A. 2  
 
ROM study measures by time interval, in alphabetical order. 
 
Note: For a list of the complete set of questionnaires used within the study see Meuldijk et al. 2012. In bold: primary and secondary outcome measures.  
T1: baseline assessment; T2: 3 month assessment; T3: 6 month assessment; T4: 12 month assessment. 
aGen: Generic cluster. bSR: Self Report, OS: Observer Scale. cMental Healthcare Thermometer (in Dutch: GGZ Thermometer) . 
BSI: Brief Symptom Inventory; CGI: Global Clinical Impression; Demog: Demographics; MINI-Plus: mini-international neuropsychiatric interview-plus; SF-36: 
Short-Form Health Survey ; WSQ: Web Screening Questionnaire. 
Instrument Full Name Domain Clustera Typeb Time- interval 
     T1 T2 T3 T4 
BSI Brief Symptom Inventory Psychopathology Gen SR X X X X 
CGI Clinical Global Impression Psychopathology Gen OS X X X X 
DEMOG Demographic Inventory Social Demographics Gen SR X    
Mental Healthcare  Dutch Mental Healthcare Thermometer  Consumer Satisfaction Gen SR  X   
Thermometerc of Appreciation by Clients        
MINI-Plus  Mini- International Neuropsychiatric Interview Plus  Psychopathology Gen OS X    
SF- 36 Short Form Health Survey 36 Psychosocial  Functioning Gen SR X X X X 
WSQ Web Screening Questionnaire for common mental  Psychopathology Gen SR X  X X 
 disorders        
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Appendix B  
 
Table B. 1  
 
Estimated mean differences for the primary outcome measures at baseline, 3 months, 8 months, and 12 months, based on intention-to-treat GEE analysis. 
 
Measure Time  Mean difference 95% CI Sig 
Primary outcomes     
 BSI Total score Baseline    0.05    
 3 months  -0.30   -0.54 to -0.06 0.01* 
 6 months  -0.10   -0.39 to  0.20 0.53 
 12 months  -0.18   -0.52 to  0.17 0.32 
     
  ORc 95% CI  
 WSQ score Baseline   0.78     
 6 months   0.76    0.16  to 3.65 0.73 
 12 months   0.78    0.17  to 3.71 0.80 
     
 
Estimated mean differences are expressed as β (95% CI) or as OR (95% CI). Standard care is reference category.  
BSI: Brief Symptom Inventory; WSQ: Web Screening Questionnaire. 
 
*Significant as p <0.05. 
 
 
 
Appendix B  
 
Table B. 2 
 
 Estimated mean differences for secondary outcomes at baseline, 3 months, 8 months, and 12 months, based on intention-to-treat GEE analysis. 
 
 
CGI: Clinical Global Impression SF-36: Short-Form Health Survey. Standard care is reference category. 
 
*Significant at p <0.01. 
**Significant at p <0.05. 
 
 
 
 
Measure Time  Mean difference 95% CI Sig 
Secondary Outcomes     
Severity of Illness (CGI score) Baseline     0.01     
 3 months   -0.57     -0.94 to  -0.20 0.003* 
 6 months   -0.20    -0.74 to   0.34 0.47 
 12 months   -0.35     -0.98 to   0.28 0.28 
     
Social Functioning (SF-36 score) Baseline    1.62      
 3 months  13.35        4.28 to 22.42 0.004* 
 6 months   -3.23     -14.76 to   8.29 0.58 
 12 months    3.29       -9.66 to 16.24 0.62 
     
Physical Functioning (SF-36 score) Baseline  -0.56       
 3 months    0.12       -5.64  to   5.88 0.97 
 6 months    4.07       -3.53  to 11.67 0.29 
 12 months    5.01       -3.87  to 13.89 0.27 
     
 General Health (SF-36 score) Baseline    1.50       
 3 months    4.21       -3.54  to 11.96 0.29 
 6 months    5.40      -3.66  to 14.46 0.24 
 12 months -31.60    -60.53 to  -2.67 0.03** 
     
